 |
AGGRASTAT ®
AGGRASTAT is an intravenous antiplatelet therapy known as a glycoprotein (GP) IIb/IIIa inhibitor.
- AGGRASTAT blocks the aggregation of platelets via fibrinogen, thereby reducing thrombus burden and improving blood supply to ischemic myocardium.
- AGGRASTAT received marketing approval from the U.S. FDA in 1998.
- AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction (MI), or refractory ischemia/repeat cardiac procedure.
- AGGRASTAT is both fast-acting and reversible, allowing for rapid inhibition of platelet activity.
For additional information, health care professionals can visit the AGGRASTAT website:.JPG)
AGGRASTAT Product & Medical Information Inquiries
Phone: 800.509.0544
|
